BCMA nanobody CAR-T cells

BCMA nanobody CAR-T cells are a form of chimeric antigen receptor T cell therapy in which the antigen-binding domain is derived from a single-domain antibody fragment known as a nanobody (VHH), specifically targeting B-cell maturation antigen (BCMA). Nanobodies offer advantages such as small size, high stability, and strong affinity. The engineered T cells express a synthetic receptor that recognizes and binds to BCMA on malignant plasma cells—most notably in multiple myeloma—leading to targeted cytotoxicity against these cancerous cells. The mechanism involves direct recognition of the tumor-associated antigen independent of MHC presentation, followed by T cell activation and tumor cell lysis. Preclinical studies and early-phase clinical trials have demonstrated that anti-BCMA nanobody-based CAR-Ts can be as effective as traditional scFv-based constructs[1][2]. These therapies are primarily being developed for relapsed/refractory multiple myeloma.

Other names

BCMA-targeted nanobody CAR-T cellsanti-BCMA nanobody CAR-TVHH-based BCMA CAR-T